HR and melanoma: ,3,4 Although the FDA recently approved the AKT inhibitor capivasertib in combination with the estrogen receptor antagonist fulvestrant for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in patients whose tumors harbor alterations in PIK3CA, AKT1, or PTEN,29 clinical trials investigating pharmacological AKT inhibitors in melanoma have shown limited efficacy.6